Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.

Journal of medicinal chemistry - 23 Apr 2020

Kazmierski Wieslaw M, Baskaran Sam, Walker Jill T, Miriyala Nagaraju, Meesala Ramu, Beesu Mallesh, Adjabeng George, Grimes Richard M, Hamatake Robert, Leivers Martin R, Crosby Renae, Xia Bing, Remlinger Katja

Abstract excerpt

Pan-genotype NS5A inhibitors underpin hugely successful hepatitis C virus (HCV) therapy. The discovery of GSK2818713 (13), a nonstructural protein 5A (NS5A) HCV inhibitor characterized by a significantly improved genotype coverage relative to first-generation NS5A inhibitor daclatasvir (DCV), is detailed herein. The SAR analysis revealed cooperative potency effects of the biphenylene, bicyclic pyrrolidine (Aoc),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Dogs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Rats, Wistar

Share to Viral Nonstructural Proteins

Share to Virus Replication

Source

Identifiers

PMID: 32202782
DOI: 10.1021/acs.jmedchem.9b02176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.PMID 32202782Read ↗

Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.Semantic proximity Read ↗

Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.Semantic proximity Read ↗

Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).Semantic proximity Read ↗

Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.Semantic proximity Read ↗

Highly potent HCV NS4B inhibitors with activity against multiple genotypes.Semantic proximity Read ↗

Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Discovery and Development of Hepatitis C Virus NS5A Replication Complex InhibitorsSemantic proximity Read ↗

Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.Semantic proximity Read ↗

Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.Semantic proximity Read ↗

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.